multiple sclerosis: A progressive autoimmune disorder affecting the central nervous system resulting in demyelination. Patients develop physical and cognitive impairments that correspond with the affected nerve fibers.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
246 |
4. Check minimum number of eventsNone |
246 |
5. Include endpointsNone |
246 |
6. Filter based on genotype QC (FinnGen only) |
223 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M35
- Name in latin
- Fibrosclerosis multifocalis
Similar endpoints
↥List of similar endpoints to
Multifocal fibrosclerosis
based on the number of shared cases.
Similar with more cases:
- Other systemic involvement of connective tissue
- Systemic connective tissue disorders
- Diseases of the musculoskeletal system and connective tissue
- Any operation in hilmo
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1805 | 1278 | 511 |
| Only index persons | 1554 | 1106 | 448 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.04 | 0.01 |
| Only index persons | 0.03 | 0.04 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 72.13 | 72.44 | 71.18 |
| Only index persons | 70.74 | 71.06 | 69.95 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 223 | 152 | 71 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.03 |
| Median age at first event (years) | 63.47 | 61.72 | 67.21 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 228
- Matched controls
- 2280
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M35.5
ICD-10 Finland
Multifocal fibrosclerosis
+∞
307.7
228
*
M35.3
ICD-10 Finland
Polymyalgia rheumatica
175.9
268.0
136
19
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
10.3
61.9
89
133
L04AX03
ATC
methotrexate; systemic
8.7
45.8
71
113
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
11.4
45.2
53
59
H02AB06
ATC
prednisolone; systemic
8.6
41.4
190
836
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
8.7
36.0
52
75
L88
ICPC
Rheumatoid/seropositive arthritis
11.1
34.6
40
43
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
+∞
34.2
32
*
P01BA02
ATC
hydroxychloroquine; oral
7.1
31.1
54
95
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
5.2
30.9
161
720
H02AB07
ATC
prednisone; oral
5.4
29.0
74
187
M31.5
ICD-10 Finland
Giant cell arteritis with polymyalgia rheumatica
318.5
28.4
28
*
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
114.6
28.4
30
*
M05BA04
ATC
alendronic acid; oral
5.7
27.2
62
141
N03AX16
ATC
[U] pregabalin
3.8
20.7
92
344
PAW37
NOMESCO Finland
Biopsy of temporal artery
218.2
19.9
20
*
M25.5
ICD-10 Finland
Pain in joint
3.2
17.0
109
502
M35.1
ICD-10 Finland
Other overlap syndromes
+∞
16.9
16
*
L04AX01
ATC
azathioprine; systemic
11.6
14.2
26
25
A02BC02
ATC
pantoprazole; systemic
3.9
13.8
192
1318
N02AX02
ATC
tramadol; systemic, rectal
2.8
13.2
130
730
M13.9
ICD-10 Finland
Arthritis, unspecified
4.5
12.9
34
85
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
6.3
12.5
22
38
M05BA07
ATC
risedronic acid; oral
5.7
12.3
24
46
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
4.0
12.0
38
109
M35.7
ICD-10 Finland
Hypermobility syndrome
126.1
11.5
12
*
M79.1
ICD-10 Finland
Myalgia
3.2
11.5
54
201
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.3
11.4
49
173
J45.9
ICD-10 Finland
Asthma, unspecified
2.8
10.8
69
305
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.6
10.8
144
909
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.9
10.6
63
267
M54.5
ICD-10 Finland
Low back pain
2.5
10.6
102
551
M54.9
ICD-10 Finland
Dorsalgia, unspecified
3.2
10.5
47
169
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
3.8
10.3
34
100
L01BA01
ATC
methotrexate; systemic
7.7
9.8
22
31
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.5
9.6
94
506
H02AB04
ATC
methylprednisolone; systemic
2.9
9.5
51
204
A07EC01
ATC
sulfasalazine; oral, rectal
3.8
9.4
31
91
H04.10
ICD-10 Finland
Dry eye syndrome
3.1
9.4
45
168
EB1AA
NOMESCO Finland
Intraoral radiographic dental examination
2.4
9.2
134
857
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
2.3
8.8
122
758
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.5
8.8
68
327
R70.0
ICD-10 Finland
Elevated erythrocyte sedimentation rate
8.4
8.5
18
23
N03AX12
ATC
[U] gabapentin; oral
2.7
8.5
55
242
A46
ICD-10 Finland
Erysipelas
2.7
8.5
53
229
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
4.5
8.4
21
50
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
3.7
8.4
28
83
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
3.2
8.1
36
128
A01
ICPC
Pain general/multiple sites
2.9
8.1
44
176
R50.9
ICD-10 Finland
Fever, unspecified
2.7
8.0
48
203
M48.0
ICD-10 Finland
Spinal stenosis
2.7
7.7
46
193
R4110
NOMESCO Finland
Physiotherapy
2.3
7.5
83
462
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.2
7.5
131
875
ZX120
NOMESCO Finland
Intravenous
2.9
7.3
37
142
M01AH05
ATC
etoricoxib; oral
2.2
7.3
149
1053
J01DB01
ATC
cefalexin; oral
2.8
7.1
197
1577
NB1AA
NOMESCO Finland
Shoulder X-ray examination without contrast
3.1
7.1
31
109
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.1
7.1
97
587
UJF30
NOMESCO Finland
Ileoscopy through colon
2.9
7.0
36
139
R07.4
ICD-10 Finland
Chest pain, unspecified
2.2
7.0
89
522
M01AE02
ATC
naproxen; oral, rectal
2.1
7.0
142
995
Z01.8
ICD-10 Finland
Other specified special examinations
2.3
6.8
62
317
I77.6
ICD-10 Finland
Arteritis, unspecified
41.3
6.8
8
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.2
6.7
28
96
L29
ICPC
Musculoskeletal sympt/complt other
2.9
6.7
34
131
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
3.3
6.6
26
86
J01FA10
ATC
azithromycin; systemic
2.1
6.6
135
941
M79.6
ICD-10 Finland
Pain in limb
2.0
6.6
116
766
M05BX04
ATC
denosumab; parenteral
3.2
6.5
27
92
SPAT1253
SPAT
Initiation, adjustment, discontinuation or repetition of medication
2.1
6.5
83
485
M06.0
ICD-10 Finland
Seronegative rheumatoid arthritis
6.3
6.4
16
27
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.6
6.4
42
184
SPAT1254
SPAT
Administration of medicine
2.4
6.4
52
252
A02BC05
ATC
esomeprazole; systemic
2.0
6.4
110
717
TNX00
NOMESCO Finland
Puncture and needle biopsy of soft tissue, unspecified region
9.7
6.4
12
13
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.3
6.3
54
269
XQ800
NOMESCO Finland
Prick test
3.4
6.2
23
73
S81.8
ICD-10 Finland
Open wound of other parts of lower leg
4.3
6.2
16
39
M02AA07
ATC
piroxicam; topical
2.0
6.2
102
653
M70.6
ICD-10 Finland
Trochanteric bursitis
2.4
6.2
48
228
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
2.6
6.1
37
156
A02BC01
ATC
omeprazole; systemic
2.1
6.0
80
473
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
92
309
4.31
24.75
1.4
1.3
9.04
15.94
u/ml
0.58
27
109
93
344
3.88
21.37
1.5
1.3
32.59
37.61
iu/ml
0.18
31
105
35
67
5.99
18.14
1.7
1.3
5.54
8.20
iu/ml
0.33
11
14
126
667
2.99
14.83
3.3
2.0
363.06
206.41
u/l
0.29
114
629
23
38
6.62
13.68
1.1
1.3
—
—
—
0
0
176
1154
3.30
13.52
15.7
9.2
4.73
4.16
e9/l
2.21
160
995
100
512
2.70
11.88
3.0
2.8
337.29
348.42
umol/l
0.53
89
429
26
56
5.11
11.74
1.5
1.4
0.01
0.03
iu/ml
—
5
12
164
1107
2.72
10.57
5.5
4.2
0.00
0.00
estimate
-0.00
43
240
162
1087
2.69
10.57
5.2
4.1
0.00
0.00
estimate
-0.00
42
252
163
1098
2.70
10.53
5.4
4.1
0.00
6.25
estimate
0.50
43
260
161
1102
2.57
9.66
8.7
6.6
1.22
1.21
mmol/l
1.17
145
943
195
1476
3.22
9.45
14.5
4.1
13.97
13.42
mm/h
0.19
183
1356
98
567
2.28
8.25
2.7
2.2
3.17
3.15
mg/l
0.03
81
487
138
924
2.25
8.07
3.8
2.5
83.70
78.83
nmol/l
1.48
132
816
66
336
2.36
7.38
3.8
3.1
3.39
2.59
e6/l
0.26
42
156
144
1006
2.17
7.25
7.8
6.1
1.22
1.21
mmol/l
0.42
134
926
116
752
2.10
7.04
3.4
3.4
1595.71
1727.48
ng/l
0.14
100
642
140
982
2.10
6.79
5.5
4.3
34.70
35.05
g/l
0.29
130
918
194
1558
2.64
6.66
13.4
7.7
77.11
81.39
u/l
0.51
186
1470
35
140
2.77
6.40
1.7
1.8
—
—
—
0
0
73
411
2.14
6.28
5.0
3.8
116.27
224.18
ng/l
0.56
58
339
40
176
2.54
6.06
4.2
3.3
76.42
88.35
ng/l
0.65
35
149
113
755
1.98
6.03
3.1
3.2
2.36
2.36
mmol/l
0.02
99
690
131
927
1.97
5.86
3.5
3.0
107.70
122.21
ug/l
0.56
121
854
132
951
1.92
5.45
2.7
2.2
93.86
95.47
pmol/l
0.15
74
472
17
49
3.67
5.28
1.4
1.3
—
—
—
0
0
23
84
2.93
4.95
1.9
2.0
32.94
40.34
u/l
1.20
23
73
10
13
7.99
4.90
1.4
1.1
—
—
—
0
0
10
13
7.99
4.90
1.4
1.1
—
—
—
0
0
10
13
7.99
4.90
1.4
1.1
—
—
—
0
0
8
7
11.78
4.82
1.1
1.1
—
—
—
0
0
97
653
1.84
4.76
3.7
3.0
32.66
30.90
u/l
0.21
91
612
76
477
1.89
4.62
3.0
2.8
2.46
2.47
mmol/l
0.41
63
430
98
670
1.81
4.52
2.9
2.4
68.23
66.31
u/l
0.06
88
614
10
15
6.91
4.52
1.4
1.1
—
—
—
0
0
10
15
6.91
4.52
1.4
1.1
—
—
—
0
0
20
72
2.95
4.41
1.4
1.2
—
—
—
0
0
147
1143
1.81
4.31
5.7
6.2
9.70
11.12
umol/l
2.24
136
1085
35
169
2.27
4.30
1.8
1.5
—
—
—
0
0
67
413
1.88
4.27
1.8
1.8
1116.30
1210.40
nmol/l
0.36
55
310
9
13
7.16
4.20
1.4
1.1
—
—
—
0
0
90
612
1.78
4.15
4.7
3.3
0.25
0.58
e6/l
1.88
74
449
9
14
6.64
4.02
1.0
1.2
—
—
—
0
0
35
176
2.17
3.90
5.6
5.7
9.26
9.96
mmol/l
0.31
35
164
9
15
6.20
3.85
1.1
1.0
—
—
—
0
0
155
1248
1.76
3.79
6.5
4.9
6.85
6.76
mmol/l
0.18
149
1184
63
394
1.83
3.79
2.1
1.9
—
—
—
0
0
74
488
1.76
3.72
2.4
2.3
—
—
—
0
0
211
1889
2.57
3.64
35.0
17.4
19.87
23.94
mg/l
1.43
194
1591
59
366
1.83
3.63
4.1
3.0
1.37
1.20
e6/l
0.12
37
187
180
1527
1.85
3.54
6.0
4.5
15.40
14.97
pmol/l
1.30
163
1364
6
6
10.22
3.51
1.3
1.3
549.50
1194.33
u/ml
—
6
6
69
454
1.75
3.47
1.4
1.3
1.12
1.96
u/ml
0.61
13
126
35
185
2.05
3.43
2.1
2.6
6.73
4.81
ug/l
0.35
27
159
37
201
2.00
3.37
2.8
2.5
29.11
29.25
u/l
0.02
28
166
17
66
2.70
3.29
1.2
1.4
—
—
—
0
0
14
49
2.98
3.25
1.1
1.2
—
—
—
0
0
90
647
1.65
3.22
5.7
4.2
0.00
0.01
estimate
0.50
43
225
48
294
1.80
3.05
2.1
1.8
—
—
—
0
0
69
469
1.68
3.04
1.8
1.6
1.37
1.49
mg/l
0.12
57
385
14
52
2.80
2.94
1.6
1.4
—
—
—
0
0
19
83
2.41
2.93
1.9
2.0
—
—
—
0
0
16
67
2.49
2.70
1.8
1.4
238.32
294.39
ug/g
—
9
42
198
1774
1.88
2.70
7.7
5.7
1.69
1.99
mu/l
3.59
184
1603
24
122
2.08
2.62
4.0
3.3
1.65
2.46
mmol/l
0.58
16
92
7
15
4.78
2.61
1.6
1.1
—
—
—
0
0
12
44
2.82
2.59
1.4
1.3
—
—
—
0
0
12
44
2.82
2.59
1.4
1.3
—
—
—
0
0
118
939
1.53
2.59
3.4
2.7
—
—
estimate
—
0
0
5
7
7.27
2.56
1.2
1.1
—
—
—
0
0
107
835
1.53
2.56
4.8
4.1
0.00
0.01
estimate
0.50
35
209
10
31
3.33
2.55
1.1
1.1
—
—
—
0
0
128
1039
1.53
2.54
3.0
2.7
—
—
—
0
0
81
600
1.54
2.43
5.0
3.6
0.00
0.00
estimate
-0.00
34
204
14
58
2.51
2.42
1.6
1.3
—
—
—
0
0
6
12
5.10
2.41
1.0
1.2
—
—
—
0
0
6
12
5.10
2.41
1.0
1.0
—
—
—
0
0
211
1948
2.12
2.37
30.4
21.4
139.73
139.69
mmol/l
0.07
205
1908
44
283
1.69
2.35
2.1
1.8
—
—
—
0
0
211
1950
2.10
2.33
30.8
21.5
3.96
3.98
mmol/l
0.54
204
1905
29
168
1.83
2.20
1.3
1.4
—
—
—
0
0
9
30
3.08
2.17
1.1
1.4
—
—
—
0
0
7
19
3.77
2.17
1.0
1.0
—
—
—
0
0
66
479
1.53
2.14
4.5
4.0
1.02
1.02
kg/l
0.30
54
309
28
163
1.82
2.10
2.9
3.1
177.51
285.97
ng/l
0.87
23
147
5
10
5.08
2.08
1.0
1.6
—
—
—
0
0
15
70
2.22
2.03
1.9
4.9
1.27
3.86
ratio
—
9
37
6
16
3.82
1.94
1.2
1.7
76.33
113.13
ng/l
—
6
16
16
79
2.10
1.90
1.9
1.9
—
—
—
0
0
40
266
1.61
1.88
8.8
6.3
2.12
0.97
mmol/l
1.11
32
223
141
1209
1.44
1.88
3.5
3.2
44.93
50.57
u/l
0.62
132
1129
6
18
3.39
1.76
1.0
1.1
—
—
—
0
0
5
13
3.91
1.72
1.2
1.5
—
—
—
0
0
5
13
3.91
1.72
1.2
1.5
—
—
—
0
0
84
666
1.41
1.70
2.2
1.7
22.54
21.40
nmol/l
0.29
77
552
22
128
1.80
1.67
3.2
3.3
25.25
24.39
mmol/l
0.55
22
128
6
19
3.21
1.67
1.5
1.6
-0.27
1.38
mmol/l
—
6
19
5
14
3.63
1.62
1.0
1.0
—
—
—
0
0
5
15
3.38
1.53
1.0
1.1
—
—
—
0
0
6
21
2.91
1.51
1.0
1.1
—
—
—
0
0
194
1798
1.53
1.48
8.4
7.0
41.21
40.13
mmol/mol
0.95
183
1666
20
118
1.76
1.47
1.3
1.2
28.50
116.10
u/ml
—
6
45
195
1816
1.51
1.38
29.8
18.1
73.97
75.48
ml/min/173m2
0.46
189
1696
106
900
1.33
1.33
5.8
4.3
27.91
40.53
ng/l
1.10
82
673
208
1968
1.65
1.33
22.3
12.3
26.16
23.70
u/l
1.11
202
1904
10
48
2.13
1.29
1.2
1.4
—
—
—
0
0
9
44
2.09
1.28
1.4
1.6
—
—
—
0
0
189
1757
1.44
1.27
4.9
4.5
1.30
1.25
mmol/l
0.52
174
1580
5
20
2.53
1.15
1.0
1.2
—
—
—
0
0
211
2014
1.64
1.15
46.8
26.7
259.57
246.85
e9/l
1.77
206
1974
211
2015
1.63
1.13
46.7
26.7
4.33
4.39
e12/l
0.99
205
1967
7
32
2.22
1.09
1.3
1.2
—
—
—
0
0
5
23
2.20
0.98
1.2
1.9
—
—
—
0
0
194
1835
1.38
0.96
6.6
5.5
5.89
6.04
mmol/l
0.83
181
1658
194
1838
1.37
0.92
5.8
5.4
4.56
4.57
mmol/l
0.05
184
1678
6
28
2.17
0.92
1.5
1.6
—
—
—
0
0
37
283
1.37
0.91
1.4
1.5
—
—
—
0
0
18
119
1.56
0.91
2.9
4.4
1.01
1.02
ratio
0.68
13
112
193
1830
1.36
0.88
5.8
5.3
1.48
1.51
mmol/l
0.47
183
1661
197
1878
1.36
0.83
6.6
6.2
2.62
2.62
mmol/l
0.01
186
1706
0
27
0.00
0.78
0.0
1.2
—
—
—
0
0
5
25
2.02
0.73
1.2
1.7
—
—
—
0
0
5
25
2.02
0.73
1.2
1.7
—
—
—
0
0
5
25
2.02
0.73
1.2
1.7
—
—
—
0
0
32
249
1.33
0.72
5.1
5.3
32.62
33.88
%
0.24
24
153
5
26
1.94
0.71
1.0
1.1
—
—
—
0
0
80
705
1.21
0.65
5.2
4.0
6.08
8.64
mg/mmol
0.65
50
435
10
64
1.59
0.59
2.1
1.5
—
—
—
0
0
0
23
0.00
0.58
0.0
1.4
—
—
—
0
0
56
482
1.21
0.58
5.9
6.1
1.99
2.82
ug/l
0.57
51
420
12
82
1.49
0.55
2.1
2.5
—
—
—
0
0
9
62
1.47
0.54
1.3
1.2
—
—
—
0
0
14
100
1.43
0.53
1.1
1.0
—
—
—
0
0
9
63
1.45
0.53
1.3
1.2
—
—
—
0
0
88
798
1.17
0.51
2.0
2.0
1.37
1.33
mmol/l
0.19
71
650
53
461
1.20
0.49
1.8
1.9
415.84
466.07
pmol/l
0.72
45
388
16
120
1.36
0.47
1.7
1.4
—
—
—
0
0
7
48
1.47
0.47
3.0
2.9
4.74
11.06
pmol/l
—
7
48
29
239
1.24
0.45
3.3
3.4
5.90
5.72
kpa
0.65
29
234
7
51
1.38
0.44
1.4
1.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
5
35
1.44
0.39
1.2
1.1
0.56
0.98
nmol/l
—
5
28
9
66
1.38
0.39
1.6
1.5
—
—
—
0
0
6
45
1.34
0.34
1.2
1.8
—
—
—
0
0
29
250
1.18
0.31
2.0
4.2
3.73
35.77
ug/l
0.63
20
209
8
63
1.28
0.28
1.3
1.6
—
—
—
0
0
8
65
1.24
0.27
1.6
1.4
—
—
—
0
0
12
95
1.28
0.27
2.8
1.9
1.11
4.30
ug/l
0.51
12
82
25
287
0.86
0.26
1.7
1.5
—
—
—
0
0
10
126
0.78
0.25
2.8
2.2
—
—
—
0
0
19
163
1.18
0.22
4.3
3.0
57.29
62.87
ml/min/173m2
—
7
69
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
2.0
—
13.60
—
0
10
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
41
376
1.11
0.20
3.5
5.3
19.05
22.03
%
0.86
22
204
0
14
0.00
0.20
0.0
2.3
—
—
—
0
0
27
242
1.13
0.19
3.1
3.8
—
—
—
0
0
6
53
1.14
0.19
3.2
4.6
32.00
30.41
mg/l
—
6
38
7
60
1.17
0.18
2.6
2.0
137.57
125.50
g/l
—
7
46
11
91
1.22
0.18
2.3
1.3
—
—
—
0
0
8
68
1.18
0.17
1.8
1.5
—
—
—
0
0
18
158
1.15
0.17
2.7
2.8
126.78
127.33
g/l
0.04
18
152
31
284
1.11
0.16
3.4
3.5
0.89
0.80
ug/l
0.26
22
190
15
134
1.13
0.11
1.9
3.2
19.48
63.32
u/ml
1.39
15
129
5
44
1.14
0.10
2.0
1.4
—
—
—
0
0
6
54
1.11
0.09
1.8
1.4
—
—
—
0
0
6
56
1.07
0.08
1.5
1.5
—
—
—
0
0
15
137
1.10
0.07
1.9
2.5
1.21
1.16
%
0.09
15
137
23
243
0.94
0.06
9.6
7.4
—
—
—
0
0
11
117
0.94
0.02
2.6
2.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
10.57
—
0
7
0
6
0.00
-0.00
0.0
1.3
—
7.30
—
0
6
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
0.22
—
0
7
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_MULTIFIBRO and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_MULTIFIBRO | 1.619 [1.38, 1.9] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.019 |
During the follow-up period (1.1.1998 — 31.12.2019), 528 out of 1187 females with M13_MULTIFIBRO died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_MULTIFIBRO | 1.371 [1.09, 1.72] | 0.006 |
| Birth year | 0.988 [0.98, 1.0] | 0.015 |
During the follow-up period (1.1.1998 — 31.12.2019), 229 out of 481 males with M13_MULTIFIBRO died.
Mortality risk
Mortality risk for people of age
years, who have M13_MULTIFIBRO.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.105% | 0.27% |
| 5 | 0.745% | 1.63% |
| 10 | 1.866% | 3.975% |
| 15 | 3.45% | 7.504% |
| 20 | 6.278% | 13.11% |
Relationships between endpoints
↥Index endpoint: M13_MULTIFIBRO – Multifocal fibrosclerosis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data